Jan.29 -- Novavax Chief Executive Officer Stan Erck discusses efficacy data from trials of the company’s Covid-19 vaccine, the time frame for approval and delivery of the vaccine, and work on a reformulated version for virus variants. He speaks on "Bloomberg Markets: European Close."